Janssen invests €150M to expand Irish biopharmaceutical facility

The expansion will take two years and add 180 new jobs. 

Janssen has been producing medicines at the site since 2005, including those for immunology and oncology patients who have illnesses such as rheumatoid arthritis, Crohn's disease, psoriasis, psoriatic arthritis and multiple myeloma. 

Today’s news follows a previous investment of €300 million in the Ringaskiddy facilities in 2017, which saw the construction of a large-scale manufacturing suite at the site. This suite will begin commercial operations shortly, after receiving all necessary manufacturing approvals.   

The expansion is supported by the Irish government via the Industrial Development Agency (IDA), who say continuous investment in the facility is serving to increase operational capacity to meet the demands of a growing clinic portfolio.  

Johnson & Johnson Vice President Manufacturing & Technical Operation, Leila Schwery-Bou-Diab, said the facility has been “at the cutting-edge of delivering life-changing healthcare products” since its establishment in 2005.  

“The additional manufacturing capacity created by this investment will enhance the work we do to deliver transformational medicines that can change the trajectory of health,” she said.  

Janssen Sciences General Manager Gary Hartnett said the continued investment in Ringaskiddy is “a real vote of confidence in the talent and dedication of our people, who I am proud to work with every single day as we strive to create a future where disease is a thing of the past.”  

In 2020, the site was designated as a Global Lighthouse site by the World Economic Forum, recognising it as one of the world’s most advanced manufacturers leading the way in the adoption of Fourth Industrial Revolution technologies. The Ringaskiddy facility also operates as a Global Centre of Excellence for Clinical Drug Substance and Drug Product Release and Stability Management.